1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Rezolute: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism Ersodetug - Tumor Hyperinsulinism (Tumor HI) | Phase 3 | Recruiting | Rezolute | 16 | 2025-04-16 | 2026-09-28 |
| RZ358 Treatment for Congenital Hyperinsulinism RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC - Congenital Hyperinsulinism | Phase 3 | Active not recruiting | Rezolute | 56 | 2024-01-11 | 2026-01-08 |
Hyperinsulinism (2) · Hypoglycemia (2) · Adenoma, Islet Cell (1) · Congenital Hyperinsulinism (1) · Digestive System Diseases (1) · Fibrosarcoma (1) · Glucose Metabolism Disorders (1) · Insulinoma (1) · Liposarcoma (1) · Metabolic Diseases (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Neuroendocrine Tumors (1) · Pancreatic Diseases (1)
Standard of Care (1)
France (2) · United Kingdom (2) · United States (2) · Bulgaria (1) · Denmark (1) · Georgia (1) · Germany (1) · Greece (1) · Netherlands (1) · Oman (1) · Qatar (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1) · Vietnam (1)
Gopal Saha, MD (1)